Atrium Therapeutics, Inc. (RNA) Price & Analysis

Compare

1 Followers

RNA Stock Chart & Stats

$15.47

-$0.39(-1.27%)

At close: Jan 08 4:00 PM EST

$15.47

-$0.39(-1.27%)

Day’s Range― - ―

52-Week Range$13.06 - $16.77

Previous CloseN/A

Volume185.29K

Average Volume (3M)2.09M

Market Cap

N/A

Enterprise Value$1.99B

Total Cash (Recent Filing)$1.70B

Total Debt (Recent Filing)$94.56M

Price to Earnings (P/E)―

BetaN/A

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding17,114,391

10 Day Avg. Volume2,820,857

30 Day Avg. Volume2,094,181

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)5.88

Price to Sales (P/S)529.62

P/FCF Ratio-14.96

Enterprise Value/Market Cap10.00T>

Enterprise Value/Revenue106.14

Enterprise Value/Gross Profit-16.47

Enterprise Value/Ebitda-2.82

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Collaboration Revenue DiversificationCollaboration revenues from research partnerships with major pharmaceutical firms contribute to non-dilutive funding and validate external interest in the technology platform.

M&A Deal ProgressAcquisition by Novartis is moving forward with a planned shareholder vote and expected regulatory approvals, supporting a clear path toward deal completion.

SpinCo Capitalization And LeadershipPlanned SpinCo will be capitalized with $270 million in cash and led by the company's Chief Program Officer, providing immediate funding and experienced leadership for independent development.

Bears Say

Analyst Risk DesignationAnalyst's Neutral rating with a High Risk designation highlights limited upside expectations and deal-related uncertainty that could pressure the stock.

Reduced Ownership In Cardiology AssetsAtrium's sole ownership of precision cardiology applications reduces the company's stake in cardiology programs and may limit future upside from those assets.

Atrium Therapeutics, Inc. News

Morning News Wrap-Up 2/27/26: Today’s Biggest Stock Market Stories!

Traders will find the best stock market stories to read on Friday in our daily wrap-up. ...

7d ago

DIA

RNA

Atrium Therapeutics launches as newly independent, publicly traded company

Atrium Therapeutics (RNA) launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to...

7d ago

NVS

RNA

Novartis completes acquisition of Avidity Biosciences

Novartis (NVS) announced that it has successfully completed its acquisition of Avidity Biosciences (RNA). With the completion of...

7d ago

NVS

RNA

Why Is Avidity Biosciences Stock (RNA) Down Today?

Avidity Biosciences stock appeared to take a beating on Friday following a deal with Novartis. ...

7d ago

NVS

RNA

One new option listing and one option delisting on February 26th

New option listings for February 26th include Avidity Biosciences, Inc. (RNAM). Option delistings effective February 26th include Avidity...

8d ago

RNA

RNA Earnings this Week: How Will it Perform?

Avidity Biosciences Inc (RNA) is scheduled to report 4th quarter earnings on 03/03/2026. Regarding Q4 estimates, Wall Street...

5d ago

RNA

Avidity Biosciences Completes Merger and Plans Nasdaq Delisting

Avidity Biosciences ( ($RNA) ) has issued an update. Following the closing of a previously agreed merger, Avidity...

7d ago

RNA

Avidity Shareholders Approve Novartis Merger and Spin-Off

Avidity Biosciences ( ($RNA) ) has provided an announcement. At a special meeting held virtually on February 26,...

8d ago

RNA

Avidity Biosciences Advances Toward Novartis Merger Completion

Avidity Biosciences ( ($RNA) ) has shared an announcement. On February 23, 2026, Avidity Biosciences, Inc. announced that...

11d ago

RNA

Avidity Plans Spin-Off Amid Novartis Acquisition Agreement

The latest update is out from Avidity Biosciences ( ($RNA) ). On February 2, 2026, Avidity Biosciences announced...

1M ago

RNA

Avidity Biosciences announces expected record date for spin-off

Avidity Biosciences (RNA) announced that its board of directors has designated the close of business, Eastern Time, on...

1M ago

NVS

RNA

Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off

New activity is brewing for Avidity Biosciences ( ($RNA) ). The company has submitted a Form DEFM14A to...

1M ago

RNA

Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI

Evercore ISI downgraded Avidity Biosciences (RNA) to In Line from Outperform with a price target of $72, up...

3M ago

RNA

Avidity reports FTC granted request for early termination of HSR waiting period

In a regulatory filing, Avidity Biosciences (RNA) noted that as previously disclosed, the company entered into an Agreement...

3M ago

NVS

RNA

RNA FAQ

What was Atrium Therapeutics, Inc.’s price range in the past 12 months?

Atrium Therapeutics, Inc. lowest stock price was $13.06 and its highest was $16.77 in the past 12 months.

What is Atrium Therapeutics, Inc.’s market cap?

Currently, no data Available

When is Atrium Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Atrium Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Atrium Therapeutics, Inc. overvalued?

According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Atrium Therapeutics, Inc. pay dividends?

Atrium Therapeutics, Inc. does not currently pay dividends.

What is Atrium Therapeutics, Inc.’s EPS estimate?

Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atrium Therapeutics, Inc. have?

Atrium Therapeutics, Inc. has 17,114,391 shares outstanding.

What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?

Currently, no hedge funds are holding shares in RNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Atrium Therapeutics, Inc.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.